PLK1 and neoplasm: An aptamer-siRNA chimera was developed where the aptamer portion of the chimeras mediated binding to PSMA, whereas the siRNA portion targeted the expression of tumor survival genes polo-like kinase 1 (Plk1)17 and Bcl-2.